Gilead, MSD chart weekly HIV med’s course to approval on SoC non-inferiority
If approved, ISL/LEN could become the first once-weekly, single-tablet HIV treatment to reach the market as patients rely on once-daily options.
23 July 2026
23 July 2026
If approved, ISL/LEN could become the first once-weekly, single-tablet HIV treatment to reach the market as patients rely on once-daily options.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.